The discovery of new biotherapeutics is one of the major sources of hope for many patients with a large variety of diseases
For them, we have to be clever, innovative, fast and efficient
For them, we have to work together and combine the best of our knowledge and talents
To them, we are dedicated
Our job at Magellan Biologics & Consulting is to contribute to this global effort by providing the lifescience community with the most advanced solutions in the field of transient protein expression in CHO cells.
Starting from you DNA construct, we offer, in a simple and user friendly way, access to:
– high titers, also with difficult-to-express proteins
– high quality and purity
– high reproducibility
Are you also involved in R&D on antibodies?
Are you planning to screen different protein variants?
We’re here to help!
– We at Magellan Biologics & Consulting proudly support the scientific community in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient protein expression in CHO cells and through personalized advices and consultancies.

A novel drug produced in CHO cells has recently been approved by the FDA
Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic